Nepafenac Once Daily for Macular Edema - Study 2

Summary

The purpose of this study is to demonstrate superiority of Nepafenac Ophthalmic Suspension, 0.3% dosed once daily relative to Nepafenac Vehicle based upon clinical outcomes among diabetic participants following cataract surgery.

Timeline

Start

2013-06

Primary completion

2015-05

Completion

2015-05

Outcome

Mixed primary results

registry NUMBER Nepafenac: 48.8 Percentage of participants NUMBER Vehicle: 50.5 Percentage of participants analysis (superiority or other test); Nepafenac vs Vehicle; p = 0.671 NCT01872611 ↗

registry NUMBER Nepafenac: 5.9 Percentage of participants NUMBER Vehicle: 14.3 Percentage of participants analysis (superiority or other test); Nepafenac vs Vehicle; p = 0.001 NCT01872611 ↗

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Nepafenac	Other / unclassified	0.3 %	Topical
Background	Prednisolone	Other / unclassified	—	Topical

Indications